MEDIDATA and clinical research organisation (CRO) Parexel have expanded their 15-year international strategic collaboration to boost the delivery of decentralised clinical trials.

The partnership expansion builds on the two firms’ relationship and establishes the goal of co-pioneering a new age of decentralised clinical trial technology (DCT) for the life sciences industry.

Parexel is also a participant in the Early Adopter DCT program of Medidata and utilises the latter’s myMedidata patient portal, Sensor Cloud, and Patient Centricity by Design programme.

The myMedidata patient portal is a combined platform of the company.

Parexel offers feedback and insights to ensure the portal fulfils the patients, sites, and sponsors’ requirements.

Leveraging myMedidata, patients can access all of their trial requirements virtually using one web-based portal, alleviating the requirement for provisioned devices as well as enhancing trial experiences.

Parexel chief patient officer Clare Grace said: “Parexel’s priority focus is on providing patient-centred solutions that enhance the clinical trial experience and make participation more accessible to everyone.

“Medidata’s DCT technologies further support our efforts in a market where nearly 75% of proposals include at least a hybrid trial model.”

A Dassault Systèmes company, Medidata aids in creating the data and insights to help pharmaceutical, biotech companies and academic researchers, among others boost value, reduce risk and streamline outcomes. 

Medidata patient Cloud CEO Anthony Costello said: “The Covid-19 pandemic showed us that we can leverage DCT technologies to expedite and enhance the entire clinical trials process.

“The relationship with Parexel represents an enormous opportunity to forever redefine the patient experience and development timelines for the development of new medicines and vaccines.”

In June last year, Medidata unveiled its DCT Program, a suite of technologies to fully decentralise the trial continuum.